HK1036219A1 - Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs - Google Patents

Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs

Info

Publication number
HK1036219A1
HK1036219A1 HK01106832A HK01106832A HK1036219A1 HK 1036219 A1 HK1036219 A1 HK 1036219A1 HK 01106832 A HK01106832 A HK 01106832A HK 01106832 A HK01106832 A HK 01106832A HK 1036219 A1 HK1036219 A1 HK 1036219A1
Authority
HK
Hong Kong
Prior art keywords
mucus
lungs
growth factor
receptor antagonists
factor receptor
Prior art date
Application number
HK01106832A
Other languages
English (en)
Inventor
Nadel A Jay
Takeyama Kiyoshi
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1036219A1 publication Critical patent/HK1036219A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01106832A 1998-08-18 2001-09-27 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs HK1036219A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9702398P 1998-08-18 1998-08-18
PCT/US1999/018696 WO2000010588A2 (en) 1998-08-18 1999-08-17 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs

Publications (1)

Publication Number Publication Date
HK1036219A1 true HK1036219A1 (en) 2001-12-28

Family

ID=22260380

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106832A HK1036219A1 (en) 1998-08-18 2001-09-27 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs

Country Status (36)

Country Link
US (6) US6270747B1 (xx)
EP (2) EP1970058A1 (xx)
JP (2) JP2002539072A (xx)
KR (1) KR100609646B1 (xx)
CN (1) CN1184961C (xx)
AR (1) AR020220A1 (xx)
AT (1) ATE399541T1 (xx)
AU (1) AU760766B2 (xx)
BR (1) BR9912672A (xx)
CA (1) CA2337422C (xx)
CO (1) CO5130028A1 (xx)
CY (1) CY1110370T1 (xx)
CZ (1) CZ2001584A3 (xx)
DE (1) DE69939022D1 (xx)
DK (1) DK1119349T3 (xx)
EA (1) EA004316B1 (xx)
EE (1) EE200100097A (xx)
ES (1) ES2310047T3 (xx)
HK (1) HK1036219A1 (xx)
HR (1) HRP20010119B1 (xx)
HU (1) HUP0103894A3 (xx)
ID (1) ID27345A (xx)
IL (2) IL140855A0 (xx)
MY (1) MY126490A (xx)
NO (1) NO327000B1 (xx)
NZ (1) NZ509271A (xx)
PH (2) PH12010000215A1 (xx)
PL (1) PL200940B1 (xx)
PT (1) PT1119349E (xx)
RS (1) RS50273B (xx)
SI (1) SI1119349T1 (xx)
SK (1) SK287805B6 (xx)
TR (1) TR200100560T2 (xx)
TW (1) TWI250019B (xx)
UA (1) UA73722C2 (xx)
WO (1) WO2000010588A2 (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
CZ2001584A3 (cs) 1998-08-18 2002-06-12 The Regents Of The University Of California Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030236300A1 (en) * 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
CA2489947A1 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
WO2004066912A2 (en) * 2003-01-31 2004-08-12 Technion Research & Development Foundation Ltd. Anti-inflammatory compositions and uses thereof
US7195899B1 (en) * 2003-03-14 2007-03-27 Florida State University Research Foundation, Inc. Cell-based biosensor for harmful airborne agents
US20050181036A1 (en) * 2003-08-26 2005-08-18 Research Development Foundation Aerosol delivery of curcumin
EP1694335A4 (en) 2003-08-26 2008-12-31 Res Dev Foundation OSTEOCLASTOGENESIS HEMMER AND ITS USES
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
AU2005288519A1 (en) * 2004-09-27 2006-04-06 Technion Research & Development Foundation Ltd. Fatty acid modified polylysines as antimicrobial agents
US7915223B2 (en) * 2004-09-27 2011-03-29 Technion Research & Development Foundation Ltd. Antimicrobial agents
JP4690158B2 (ja) * 2004-09-28 2011-06-01 スギ生物科学研究所株式会社 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
WO2006035706A1 (ja) * 2004-09-28 2006-04-06 Dainippon Ink And Chemicals, Inc. 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
JP2009511586A (ja) * 2005-10-11 2009-03-19 ワシントン・ユニバーシティ 気道分泌過多を治療するための組成物および方法
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) * 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
US20080293740A1 (en) * 2007-04-03 2008-11-27 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders
US20100173832A1 (en) * 2007-04-30 2010-07-08 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
WO2008132737A1 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
EA019709B1 (ru) * 2008-02-07 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Спирогетероциклы и их применение в качестве лекарственных средств
CA2733153C (en) * 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US8597695B1 (en) 2010-11-13 2013-12-03 Sirbal Ltd. Herbal combinations for treatment of a skin condition
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
EP3513787A1 (en) * 2011-01-10 2019-07-24 Invion, Inc Use of beta-adrenergic inverse agonists for smoking cessation
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
EP3498288A1 (en) 2013-12-02 2019-06-19 Sirbal Ltd. Herbal combinations for treatment of a skin condition
WO2017019651A1 (en) 2015-07-29 2017-02-02 Sirbal Ltd. Herbal combinations for treating psoriasis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932481A (en) * 1954-06-15 1960-04-12 Breer Bipod camera support
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
FR2502627A1 (fr) * 1981-02-02 1982-10-01 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1173549B (it) * 1984-04-02 1987-06-24 Corvi Camillo Spa Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4904786A (en) * 1986-01-27 1990-02-27 American Home Products Corporation Quinoline compounds as antiallergic and antiinflammatory agents
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1990003374A1 (en) * 1988-09-28 1990-04-05 The Upjohn Company 1,4-dihydrothionapthoquinone and heterocyclic congeners which inhibit lipoxygenase enzymes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
HU219537B (hu) * 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
US5116616A (en) * 1991-04-29 1992-05-26 Bio-Technology General Corp. Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
DE4310051A1 (de) 1992-04-11 1993-10-14 Byk Gulden Lomberg Chem Fab Weitere Verwendung substituierter Pyridazine
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
WO1994006283A1 (en) * 1992-09-11 1994-03-31 The Regents Of The University Of Michigan Non-human animal with xenograft of on airway populated by human cells
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
WO1995006764A2 (en) 1993-09-03 1995-03-09 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
DK0719412T3 (da) * 1993-09-13 1999-07-19 Merck Frosst Canada Inc Fremgangsmåde til måling af metaplastiske ændringer i slimsecernerende epithelceller
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
WO1995023225A2 (en) 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US20030114379A1 (en) * 1994-03-08 2003-06-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
WO1998004133A1 (en) * 1996-07-29 1998-02-05 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
CZ2001584A3 (cs) 1998-08-18 2002-06-12 The Regents Of The University Of California Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
CA2387351C (en) * 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
ES2280375T3 (es) 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion.
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Also Published As

Publication number Publication date
CY1110370T1 (el) 2015-04-29
CO5130028A1 (es) 2002-02-27
PL351765A1 (en) 2003-06-16
PH12010000215A1 (en) 2015-07-27
EA200100136A1 (ru) 2001-10-22
US20030148990A1 (en) 2003-08-07
KR100609646B1 (ko) 2006-08-04
US20080175797A1 (en) 2008-07-24
IL140855A (en) 2011-02-28
TWI250019B (en) 2006-03-01
CZ2001584A3 (cs) 2002-06-12
US7358222B2 (en) 2008-04-15
EP1119349A2 (en) 2001-08-01
UA73722C2 (en) 2005-09-15
YU13201A (sh) 2005-07-19
SK2162001A3 (en) 2002-08-06
US6551989B2 (en) 2003-04-22
DE69939022D1 (de) 2008-08-14
IL140855A0 (en) 2002-02-10
PT1119349E (pt) 2008-10-14
NZ509271A (en) 2003-10-31
HRP20010119B1 (en) 2008-05-31
TR200100560T2 (tr) 2002-05-21
US8048844B1 (en) 2011-11-01
EE200100097A (et) 2002-06-17
NO20010749D0 (no) 2001-02-14
EP1970058A1 (en) 2008-09-17
ATE399541T1 (de) 2008-07-15
NO327000B1 (no) 2009-03-30
AU760766B2 (en) 2003-05-22
AU5676699A (en) 2000-03-14
DK1119349T3 (da) 2008-10-13
AR020220A1 (es) 2002-05-02
US20010041178A1 (en) 2001-11-15
CA2337422C (en) 2010-11-02
CN1354657A (zh) 2002-06-19
US20010036919A1 (en) 2001-11-01
EA004316B1 (ru) 2004-02-26
CA2337422A1 (en) 2000-03-02
US8071074B2 (en) 2011-12-06
ES2310047T3 (es) 2008-12-16
PH12010000216A1 (en) 2015-07-27
SI1119349T1 (sl) 2008-12-31
WO2000010588A3 (en) 2001-05-25
HRP20010119A2 (en) 2002-02-28
WO2000010588A9 (en) 2000-08-10
JP2009221212A (ja) 2009-10-01
RS50273B (sr) 2009-07-15
ID27345A (id) 2001-04-05
KR20010085412A (ko) 2001-09-07
JP2002539072A (ja) 2002-11-19
NO20010749L (no) 2001-04-17
US6566324B2 (en) 2003-05-20
CN1184961C (zh) 2005-01-19
WO2000010588A2 (en) 2000-03-02
HUP0103894A2 (hu) 2002-04-29
MY126490A (en) 2006-10-31
PL200940B1 (pl) 2009-02-27
US6270747B1 (en) 2001-08-07
HUP0103894A3 (en) 2003-07-28
BR9912672A (pt) 2002-06-11
SK287805B6 (sk) 2011-10-04
EP1119349B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
PL351765A1 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
IL139030A0 (en) Therapeutic angiogenic factors and methods for their use
PL341596A1 (en) Pharmacological composition for treating concentration disorders and hyperkinesia
EP1200086A4 (en) THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
IL137413A0 (en) Methods and apparatus for calcification scoring
HUP9900163A2 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
PL348107A1 (en) Therapy for improving cognition
HUP9904109A3 (en) Local anesthetic for external use
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
AU142196S (en) Tissue
HUP0104543A3 (en) Lime treatment
HUP0200738A2 (hu) Eljárás az inkontinencia kezelésére
GB9928837D0 (en) Novel bone cement
PL352479A1 (en) Application of hydrocortisone antagonists in treating cardiac insufficiencies
HUP0102772A3 (en) Novel compounds derived from alpha-d-xylose, preparation method and therapeutic use
AU142195S (en) Tissue
GB2347965B (en) Template and method for use thereof
EP0941111A4 (en) HEPATOCYTE GROWTH FACTOR ANTAGONISTS
GB9906130D0 (en) Compounds for use in therapy
AU142197S (en) Tissue
GB9923117D0 (en) Insect-paper and methods for its formation and use
GB9824573D0 (en) Methods for stimulating bone formation
SI1117403T1 (en) Mglur5 antagonists for the treatment of pain and anxiety
TW382324U (en) Improvement for structure of facial tissue
TW356713U (en) Apparatus used for stopping the snore of sleeper

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120817